Sign In
Buy PAVM
$4.68
-0.230 (-4.68%)
At Close: Jun 23, 2026
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
09:01am, Monday, 10'th Mar 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
04:45pm, Wednesday, 05'th Mar 2025
NEW YORK , March 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAV
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
08:25am, Tuesday, 04'th Mar 2025
NEW YORK , March 4, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAV
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
08:31am, Thursday, 27'th Feb 2025
Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUC
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
08:31am, Tuesday, 25'th Feb 2025
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVme
PAVmed and Subsidiary Veris Health Complete Private Placement Financing
08:31am, Monday, 24'th Feb 2025
Gross proceeds of approximately $2.4 million from sale of PAVmed securities priced at-the-market and Veris common stock priced at a $35 million pre-money valuation NEW YORK , Feb. 24, 2025 /PRNewswire
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
08:31am, Thursday, 20'th Feb 2025
LEAA Health membership-based concierge patients will now have access to EsoGuard esophageal precancer testing as part of their enhanced personalized care service on a cash-pay basis NEW YORK , Feb. 20
PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement
08:30am, Tuesday, 18'th Feb 2025
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device,
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
08:57am, Thursday, 06'th Feb 2025
NEW YORK , Feb. 6, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
07:56am, Monday, 13'th Jan 2025
Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent NEW YORK , Jan. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"),
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
08:01am, Monday, 23'rd Dec 2024
NEW YORK , Dec. 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters
08:01am, Thursday, 19'th Dec 2024
Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lu
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
08:01am, Wednesday, 11'th Dec 2024
Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing NEW
New convertible debt financing with existing long-term equity shareholders yields ~$18M in net cash proceeds after paying off existing convertible debt NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Lucid D
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
07:56am, Wednesday, 20'th Nov 2024
NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed
